Literature DB >> 27679516

The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.

Thaigarajan Parumasivam1, Sharon S Y Leung1, Patricia Tang1, Citterio Mauro2, Warwick Britton3,4, Hak-Kim Chan5.   

Abstract

The routine of loading multiple capsules for delivery of high-dose antibiotics is time consuming, which may reduce patient adherence to inhaled treatment. To overcome this limitation, an investigation was carried out using four modified versions of the Aerolizer® that accommodate a size 0 capsule for delivery of high payload formulations. In some prototypes, four piercing pins of 0.6 mm each were replaced with a single centrally located 1.2-mm pin and one-third reduced air inlet of the original design. The performance of these inhalers was evaluated using spray-dried antibiotic powders with distinct morphologies: spherical particles with a highly corrugated surface (colistin and tobramycin) and needle-like particles (rifapentine). The inhalers were tested at capsule loadings of 50 mg (colistin), 30 mg (rifapentine) and 100 mg (tobramycin) using a multistage liquid impinger (MSLI) operating at 60 L/min. The device with a single pin and reduced air inlet showed a superior performance than the other prototypes in dispersing colistin and rifapentine powders, with a fine particle fraction (FPF wt% <5 μm in the aerosol) between 62 and 68%. Subsequently, an Aerolizer® with the same configuration (single pin and one-third air inlet) that accommodates a size 00 capsule was designed to increase the payload of colistin and rifapentine. The performance of the device at various inspiratory flow rates and air volumes achievable by most cystic fibrosis (CF) patients was examined at the maximum capsule loading of 100 mg. The device showed optimal performance at 45 L/min with an air volume of 1.5-2.0 L for colistin and 60 L/min with an air volume of 2.0 L for rifapentine. In conclusion, the modified size 00 Aerolizer® inhaler as a low-cost generic device demonstrated promising results for delivery of various high-dose formulations for treatment of lung infections.

Entities:  

Keywords:  aerosolisation; dry powder inhaler; high-dose delivery; lung infection; modified Aerolizer®

Mesh:

Substances:

Year:  2016        PMID: 27679516     DOI: 10.1208/s12248-016-9988-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  39 in total

1.  Effects of device and formulation on in vitro performance of dry powder inhalers.

Authors:  Wallace P Adams; Sau L Lee; Robert Plourde; Robert A Lionberger; Craig M Bertha; William H Doub; Jean-Marc Bovet; Anthony J Hickey
Journal:  AAPS J       Date:  2012-04-05       Impact factor: 4.009

2.  A novel dry powder inhaler: Effect of device design on dispersion performance.

Authors:  Parthiban Selvam; Doug McNair; Randall Truman; Hugh D C Smyth
Journal:  Int J Pharm       Date:  2010-08-10       Impact factor: 5.875

3.  [Resistances of dry powder inhalers and training whistles and their clinical significance].

Authors:  Tetsuri Kondo; Toshimori Tanigaki; Makoto Hibino; Motoki Ohe; Sakurako Kato
Journal:  Arerugi       Date:  2014-12

4.  Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®).

Authors:  Qi Tony Zhou; Zhenbo Tong; Patricia Tang; Mauro Citterio; Runyu Yang; Hak-Kim Chan
Journal:  AAPS J       Date:  2013-02-01       Impact factor: 4.009

5.  Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older.

Authors:  H A Tiddens; D E Geller; P Challoner; R J Speirs; K C Kesser; S E Overbeek; D Humble; S B Shrewsbury; T A Standaert
Journal:  J Aerosol Med       Date:  2006

6.  Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.

Authors:  Paul M Young; Rania O Salama; Bing Zhu; Gary Phillips; John Crapper; Hak-Kim Chan; Daniela Traini
Journal:  Drug Dev Ind Pharm       Date:  2014-05-09       Impact factor: 3.225

7.  Solid-state properties of tobramycin.

Authors:  A K Dash; R Suryanayanan
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

Review 8.  Colistin for lung infection: an update.

Authors:  Mohan Gurjar
Journal:  J Intensive Care       Date:  2015-01-22

Review 9.  Inhaled therapy in cystic fibrosis: agents, devices and regimens.

Authors:  Penny Agent; Helen Parrott
Journal:  Breathe (Sheff)       Date:  2015-06

Review 10.  Efficacy and safety of inhaler steroids in COPD patients: Systematic review and meta-analysis of randomized placebo-controlled trials.

Authors:  Reza Karbasi-Afshar; Jafar Aslani; Mostafa Ghanei
Journal:  Caspian J Intern Med       Date:  2014
View more
  3 in total

Review 1.  Administration of dry powders during respiratory supports.

Authors:  Wei-Ren Ke; Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Patricia Tang; Lan Chen; Donghao Chen; Hak-Kim Chan
Journal:  Ann Transl Med       Date:  2021-04

2.  Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication.

Authors:  S Sommerfeld Ross; S Gharse; L Sanchez; J Fiegel
Journal:  Int J Pharm       Date:  2017-08-04       Impact factor: 5.875

Review 3.  Inhalation delivery technology for genome-editing of respiratory diseases.

Authors:  Michael Y T Chow; Rachel Yoon Kyung Chang; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2020-06-05       Impact factor: 15.470

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.